QBIO Stock Overview
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Q BioMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.015 |
| 52 Week Low | US$0.000001 |
| Beta | 81.01 |
| 1 Month Change | -33.33% |
| 3 Month Change | -71.43% |
| 1 Year Change | -98.55% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| QBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 100.0% | 1.0% | 1.2% |
| 1Y | -98.6% | 0.7% | 24.9% |
Price Volatility
| QBIO volatility | |
|---|---|
| QBIO Average Weekly Movement | 10,090.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Denis Corin | www.qbiomed.com |
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. Fundamentals Summary
| QBIO fundamental statistics | |
|---|---|
| Market cap | US$29.02k |
| Earnings (TTM) | -US$1.91m |
| Revenue (TTM) | US$209.29k |
0.1x
P/S Ratio0.0x
P/E RatioIs QBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QBIO income statement (TTM) | |
|---|---|
| Revenue | US$209.29k |
| Cost of Revenue | US$221.90k |
| Gross Profit | -US$12.60k |
| Other Expenses | US$1.90m |
| Earnings | -US$1.91m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | -6.02% |
| Net Profit Margin | -912.15% |
| Debt/Equity Ratio | -63.4% |
How did QBIO perform over the long term?
See historical performance and comparison